Literature DB >> 25845386

Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.

Chen-Sung Lin1, Shi-Chuan Chang2, Liang-Hung Ou3, Chien-Ming Chen4, Sophie Swen-Wan Hsieh5, Yu-Ping Chung5, Kuang-Liang King3, Shoei-Loong Lin6, Yau-Huei Wei7.   

Abstract

We analyzed the changes in mitochondrial DNA (mtDNA) copy numbers and the shifting of mtDNA D310 sequence variations (D310 mutation) with their relationships to pathological status and the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2/neu), tumor-suppressor protein p53 and cellular proliferation protein Ki-67 in breast invasive ductal carcinoma (BIDC), respectively. Fifty-one paraffin-embedded BIDCs and their paired non-cancerous breast tissues were dissected for DNA extraction. The mtDNA copy number and mtDNA D310 sequence variations were determined by quantitative real-time polymerase chain reaction (q-PCR) and PCR-based direct sequencing, respectively. The expression levels of ER, PR, HER-2/neu, p53 and Ki-67 were determined by immunohistochemical (IHC) staining. Compared to the paired non-cancerous breast tissues, 24 (47.1%) BIDCs had elevated mtDNA copy numbers and 29 (56.9%) harbored mtDNA D310 mutations. Advanced T-status (p=0.056), negative-ER (p=0.005), negative-PR (p=0.007), positive-p53 (p=0.050) and higher Ki-67 (p=0.004) expressions were related to a higher mtDNA copy ratio. In addition, advanced T-status (p=0.019) and negative-HER-2/neu expression (p=0.061) were associated with mtDNA D310 mutations. In conclusion, higher mtDNA copy ratio and D310 mutations may be relevant biomarkers correlated with pathological T-status and the expression levels of ER, PR, HER-2/neu, p53 and Ki-67 in BIDCs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25845386     DOI: 10.3892/or.2015.3887

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma.

Authors:  Chen-Sung Lin; Hui-Ting Lee; Ming-Huei Lee; Siao-Cian Pan; Chen-Yeh Ke; Allen Wen-Hsiang Chiu; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2016-05-25       Impact factor: 5.923

2.  Altered mitochondrial DNA copy number contributes to human cancer risk: evidence from an updated meta-analysis.

Authors:  Liwen Hu; Xinyue Yao; Yi Shen
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

3.  D-loop Mutations in Renal Cell Carcinoma Improve Predictive Accuracy for Cancer-Related Death by Integrating with Mutations in the NADH Dehydrogenase Subunit 1 Gene.

Authors:  Hakushi Kim; Tomoyoshi Komiyama; Masahiro Nitta; Yoshiaki Kawamura; Masanori Hasegawa; Sunao Shoji; Yasushi Orihashi; Chie Inomoto; Hiroshi Kajiwara; Naoya Nakamura; Hiroyuki Kobayashi; Akira Miyajima
Journal:  Genes (Basel)       Date:  2019-12-02       Impact factor: 4.096

4.  Analysis of mitochondrial DNA copy number variation in blood and tissue samples of metastatic breast cancer patients (A pilot study).

Authors:  Neeraj Kumar Rai; Ghanish Panjwani; Ashok Kumar Ghosh; Rizwanul Haque; Lokendra Kumar Sharma
Journal:  Biochem Biophys Rep       Date:  2021-02-03

5.  Metabolic Reprogramming in Response to Alterations of Mitochondrial DNA and Mitochondrial Dysfunction in Gastric Adenocarcinoma.

Authors:  Tzu-Ching Chang; Hui-Ting Lee; Siao-Cian Pan; Shih-Han Cho; Chieh Cheng; Liang-Hung Ou; Chia-I Lin; Chen-Sung Lin; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

6.  Mitochondrial DNA Mutation Analysis in Breast Cancer: Shifting From Germline Heteroplasmy Toward Homoplasmy in Tumors.

Authors:  Carlos Jhovani Pérez-Amado; Hugo Tovar; Laura Gómez-Romero; Fredy Omar Beltrán-Anaya; Verónica Bautista-Piña; Carlos Dominguez-Reyes; Felipe Villegas-Carlos; Alberto Tenorio-Torres; Luis Alberto Alfaro-Ruíz; Alfredo Hidalgo-Miranda; Silvia Jiménez-Morales
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.